An Updated Mini Review of Vitamin D and Obesity: Adipogenesis and Inflammation State

Zujaja-Tul-Noor Hamid Mehmood, Dimitrios Papandreou*

College of Natural and Health Sciences, Zayed University, Abu Dhabi, United Arab Emirates

Abstract

Vitamin D related research continues to expand and theorise regarding its involvement in obesity, as both hypovitaminosis D and obesity strike in pandemic proportions. Vitamin D plays an important role in immune system through Vitamin D Receptors (VDR), which are transcription factors located abundantly in the body. Due to this characteristic, it is potentially linked to obesity, which is a state of inflammation involving the release of cytokines from adipose tissue, and exerting stress on other organs in a state of positive energy balance. Research trials in the past couple of years and systematic reviews from SCOPUS and MEDLINE will be discussed. The role of Vitamin D throughout the lifespan (from fetal imprinting until older age), and in various other obesity mediated chronic conditions shall be highlighted. Various mechanisms attributed to the inverse relationship of Vitamin D and obesity are discussed with research gaps identified, particularly the role of adipokines, epigenetics, calcium and type of adipose tissue.

Introduction

This study reviews articles available on PUBMED, Scopus and Google using the following search keywords: (Vitamin D OR Ergocalciferol OR Cholecalciferol) AND (Leptin/ adiponectin/ VDR/ inflammation/ adiposity/ body fat/ weight). The search was limited to articles in the English language until June 2016. Selected articles were also used to identify further relevant studies. Most relevant research articles were included; usually, review articles and meta-analysis to present an analysed picture of clinical trials regarding relevant information.

Vitamin D is a micronutrient that is categorically non-essential due to the endogenous production in the body with the aid of specific ultraviolet rays, but it has now become an essential component of diet as Vitamin D deficiency now engulfs the world as a pandemic [1]. This idea was established many years ago as Vitamin D inadequacy was observed even among people living closer the equator [2]. Hence, regulations directing fortification of food is either implemented or are under consideration [3]. In the 2011 conference of Institute of Medicine (IOM), the Recommended Dietary Allowance (RDA) (average daily level of intake sufficient to meet the nutrient requirements of nearly all (97%-98%) healthy people) for Vitamin D was set at 600 IU/d for ages 1-70 years and 800 IU/d for ages 71 years and older [4]. According to the Institute of Medicine (IOM) Committee, the scientific evidence supports the key role of Vitamin D in skeletal health and extra-skeletal health; however, the extra-skeletal health outcomes are not yet consistent to establish a cause-and-effect relationship [4]. Doses to treat and/or maintain Vitamin D status are still subjective and research studying the needs across different life spans and conditions continue. Vitamin D status now conjoin many other health conditions after the discovery of Vitamin D binding proteins and their receptors in many tissues [5]. Vitamin D binding receptors (VDR) are transcription factor responsible for extensive biological responses. It is shown to play a role in cell proliferation inhibition, cell maturation, immune
system, and possibly colonic, breast and prostate cancer [6]. Vitamin D status is influenced by sun exposure, adiposity, body composition, race/ethnicity, and genetic factors, but these need elucidations through research, as suggested by IOM [6].

Vitamin D deficiency has been historically defined and recently recommended by the Institute of Medicine (IOM) as a 25(OH)D of less than 20 ng/ml. Vitamin D insufficiency has been defined as a 25(OH)D of 21–29 ng/ml. Vitamin D deficiency results in abnormalities in calcium, phosphorus, and bone metabolism. Specifically, vitamin D deficiency causes a decrease in the efficiency of intestinal calcium and phosphorus absorption of dietary calcium and phosphorus, resulting in an increase in PTH levels. Secondary hyperparathyroidism maintains serum calcium in the normal range at the expense of mobilising calcium from the skeleton and increasing phosphorus wasting in the kidneys. The PTH-mediated increase in osteoclastic activity creates local foci of bone weakness and causes a generalised decrease in bone mineral density (BMD), resulting in osteopenia and osteoporosis. Phosphaturia caused by secondary hyperparathyroidism results in a low normal or low serum phosphorus level. This results in an inadequate calcium-phosphorus product, causing a mineralisation defect in the skeleton. This results in an inadequate calcium-phosphorus product, causing a mineralisation defect in the skeleton [7].

A major health issue linked with Vitamin D is the growing obesity rate. World Health Organization states that in 2014 more than 1.9 billion adults were overweight, of which 600 million were obese. According to the Global Burden of Disease report of USA, the potentially avoidable risk factors to rising disease burden included high BMI and physical inactivity for the healthy years lost [8]. Healthy years measure the expected number of years a person of a certain age could live without disability or be free of any activity limitation. Despite increased levels of sufficient physical activity in male and female, only 9 countries experienced a decline in obesity rate in the United States (with statistically insignificant results) compared to increment in the rest of the counties in obesity during 2001 and 2009 [8]. Systematic analysis to study Global, regional and national prevalence of overweight and obesity in children and adults 1980-2013 did not report any significant decline in rate over the past 33 years, but only a slowdown in increase rate of overweight and obesity was observed just in developed countries [9]. This is not satisfactory, as it indicates that an increasing obesity trend endures in other countries. This demands special attention from the public health sector to search and address socioeconomic implications in maintaining Vitamin D. To explain the deficiency of this fat-soluble vitamin in people with excessive adipocytes, the following possible mechanisms have been suggested: lower dietary intake; altered behavior that reduces cutaneous synthesis, reduced synthetic capacity, reduced intestinal absorption, altered metabolism, and sequestration in adipose tissue [10,11]. However, extensive research is needed to establish a cause-effect relationship and explain these factors under various conditions, because Vanlint concluded in his review that the evidence for vitamin D affecting fat mass and distribution is not yet compelling, and it is difficult to determine which effects are due to vitamin D itself and which are mediated via calcium when based on evidence from in vitro studies [11].

Finally, this article highlights how these public health issues of Vitamin D with its immune-related properties are associated with obesity, which is a state of low-grade inflammation. Various gaps identified by IOM committee is briefly reviewed, such as, non-skeletal health outcomes, epigenetic role, physiology and pathways of Vitamin D [4]. Researchers have previously reviewed data on this topic, [12, 14, 15], but due to constant addition of knowledge in this area we considered updating. Unlike some previous articles, we have concentrated on discussing Vitamin D and inflammatory properties in obesity, and further supplemented suggested mechanisms with clinical studies.

Obesity, a state of low-grade inflammation

Ectopic fat storage, due to overflow from adipose tissues upon fat overloading leads to the formation of foam cells from macrophages that engulf fat droplets during transportation or storage. Macrophages phagocitize lipid droplets in weight loss from adipocytes that could describe basic inflammatory nature of adipocytes. Hyperplasia and hypertrophy of adipocytes can cause mitochondrial and endoplasmic stress, which during fat overloading releases additional inflammatory cytokines other than adipokines, attracting more macrophages. During adipocytes hypertrophy TNF-α (Tumor Necrosis Factor-alpha), IL-6 (Interleukin-6), IL-1β (Interleukin-1 Beta), PG-E2 (Prostaglandin E2) expression is induced, adipocytes die and neutrophils, monocytes and T-Cells are persistently activated. CRP is also enhanced in the liver to respond to inflammatory cytokines, amplifying the cytokines pro-inflammatory effect. Hyperplastic adipocytes also induce genes TNF-α, interleukins (IL)-1, IL-6, monocyte chemoattractant protein-1 (MCP-1), and plasminogen activator inhibitor-1 (PAI-1) due to hypoxia from clustered formation, which are distant from the vasculature. Macrophages embedded in adipocytes phagocitize lipid droplets and engulf dead adipocytes that burst from high lipid accumulation, releasing reactive oxygen species and inducing further cellular stress [16]. The unfolded protein response (UPR) to
cope with Endoplasmic Reticulum (ER) stress promotes NF-κB (nuclear factor kappa-B) and JNK (c-Jun N-terminal kinases) inflammatory pathways due to increased protein demand such as in hyperglycemia, or during accumulation of misfolded protein. Excessive nutrient influx increases superoxide production and reactive oxygen species by mitochondria. The down-regulation of autophagy in the liver of lipid droplets in hepatocytes associated with obesity leads to accumulation of triglyceride, ER stress and Insulin resistance [17].

Visceral or subcutaneous fat in obesity-related inflammation is still questionable due to variability in results. A study investigating concentrations of pro-inflammatory enzymes presented higher concentration of IL-6 and IL-15 (Interleukin-15) in Subcutaneous Adipose Tissue (SAT) synthesis compared to Visceral Adipose Tissue (VAT). However, obesity was associated with VAT, since IL-6 and IL-15 were significantly more in obese individuals compared to normal-weight ones, whereas, the cytokines difference was not significant between two groups in SAT related cytokines expression [18]. On the other hand, some studies do suggest increased pro-inflammatory cytokines expression in SAT compared to VAT proposing its contribution to meta-inflammation [18, 19]. In conclusion, visceral fat compared to subcutaneous fat may cause metabolic abnormalities by secreting inflammatory adipokines, such as interleukin, tumour necrosis factor-α, macrophage chemotactrant protein-1, and resistin, which induce insulin resistance and diabetes and Vitamin D metabolic abnormalities.

**Role of Vitamin D in obesity and suggested mechanisms**

Research to explore the relationship between Vitamin D and obesity gains interest, because studies investigating obesity (a state of low-grade inflammation) and Vitamin D (with its role in immunity) indicate potential links. Many studies report changes in Vitamin D status with BMI changes. A change in serum Vitamin D levels as a function of adiposity/weight loss was noted over 1-2 years [20, 21]. An inverse relationship between Vitamin D and BMI was recognised in Mendelian randomization analysis, [22] and a link with abdominal visceral or subcutaneous adipose tissue was also recognised [23, 24]. In a meta-Analysis of observational studies up to April 2014 in PubMed/Medline, Vitamin D deficiency was prevalent in obese subjects irrespective of age, latitude and cut-offs defining vitamin D deficiency [14].

Another meta-analysis of literature focusing on the last 5 years proposed various mechanisms to discern body weight and Vitamin D relationship, which include: Vitamin D Receptor (VDR) polymorphism shown in transgenic mice and its overexpression in adipocytes that led to fatty acid β-oxidation, lipolysis and reduced energy metabolism; increased parathyroid hormone levels in Vitamin D deficiency that can increase adiposity by influx of calcium into adipocytes promoting lipogenesis; Vitamin D as "essential factor" in leptin depletion which may contribute to increased appetite and obesity in Vitamin D deficient conditions; and outdoor activity, food intake and exercise which can also influence Vitamin D levels as confounding factors [25].

Adipokines relationship with Vitamin D is studied due to their role in obesity. In vitro leptin, secretion by adipose tissue is powerfully inhibited by Vitamin D deficiency [12]. Although clinical trials showed an increase in serum leptin with Vitamin D supplementation, [26, 27] the clinical significance remains to be asserted [12, 28]. A significant effect of Vitamin D supplementation on adiponectin and leptin was not observed in a meta-analysis of 9 Randomized Controlled Trials (RCT) [29]. Serum changes in Vitamin D were significantly associated with plasma leptin levels, independent of plasma adiponectin concentrations. Further larger clinical trials and meta-analysis to effectively review these adipokines, especially focusing on obesity, are needed, as more meta-analysis could not be found.

The dose-response relationship between serum Vitamin D levels have changed and BMI showed a quadratic curve in a research involving various Vitamin D3 doses that suggested rate-limiting mechanism to avoid excessive formation of 1,25-(OH)2D3 (the active metabolite) [30]. The dose-response curves, although parallel, were noted for their difference between the curves, which was approximately 17.5 nmol/L lower for obese subjects compared to normal ones, and approximately 12.5nmol/L lower levels in overweight compared to normal-weight subjects. Extracellular pool size was suggested as the potential factor in this discrepancy rather than fat [29].

Vitamin D-metabolizing enzymes are expressed differently in Adipose tissue as well. There was decreased expression of the 25-hydroxylase CYP2J2 and the 1α-hydroxylase CYP27B1 (which converts 25(OH)D3 to the active 1,25(OH)2D3) in Subcutaneous adipose tissue, and increased expression of CYP24A1 (which inactivates calcitriol binding and activating VDR) after weight loss [30].

Calcium-sensing receptors (CaSR) gene and protein expression were found similar in white adipose tissue of obese and control mice group. Obese group had lower serum vitamin D and amino acid concentrations, and significantly higher serum triglyceride (TG), total cholesterol (TC), low-density lipoprotein-cholesterol (LDL-C), TNF-α, IL-6 and PTH levels, which suggests that Calcium-sensing receptors
function through allosteric regulation [31]. CaSR elevates pro-inflammatory cytokines in adipose tissue and decreases cyclic AMP, protein kinase A activity, hormone-sensitive lipase and adipose triglyceride lipase that are key players in the lipolytic pathway [32]. Low Calcium-induced 1,25-di(OH)₂D₃ secretion upregulates CaSR expression in adipose tissue, which is followed by an increase in [Ca²⁺] and reduced lipolysis, and possibly lipogenesis finally yielding fat accumulation in adipocytes. It was shown that higher BMI shows a greater increase in CaSR protein and thus more pro-inflammatory cytokines secreted from obese tissue [33].

Studies in relationship to Vitamin D and obesity in general population

Obesity in adults is not only of concern for their reduced productivity in life but it may also affect new lives. Observational studies and animal studies now propose and explore the mechanism about how maternal BMI and offspring adiposity from an early age are independently associated, and how in-utero environmental exposures increase susceptibility to obesity and are related to cardiometabolic disorders in later life [34, 35]. An increased risk of prenatal and early postnatal overweight in offspring (1st year of life) was found, which was attenuated by 4 years of age [36]. Vitamin D status during pregnancy could have an epigenetic role since it is not only pivotal in maternal skeletal maintenance and fetal skeletal development, but it could influence fetal "imprinting", which can affect chronic disease susceptibility soon after birth [37]. Decreased placental expression of VDR in the placenta may be a contributing factor to the pathology of idiopathic FGR (Fetal Growth Restricted)-affected pregnancies [38]. Maternal vitamin D deficiency during pregnancy was associated with impaired lung development in 6-year-old offspring; neurocognitive difficulties at the age of 10, an increased risk of eating disorders in adolescence, and lower peak bone mass at the age of 20 after relevant covariates were adjusted. Randomised controlled trials with long-term follow-up of offspring are required to examine beneficence for offspring and to determine the optimal level of maternal serum 25(OH)D for fetal development [39].

Optimal Vitamin D level is also essential from the adolescent years until the old age that is needed for health benefits. Serum Vitamin D levels decline with puberty onset, and holds a higher risk for obesity, and much greater for Insulin Resistance in pre-pubertal children with suboptimal Vitamin D serum levels [40, 41]. Hypovitaminosis D in overweight or obese adults is registered in many studies, usually accompanied with other health conditions. Mice on high-fat diet and low-fat diet was treated with calcitriol to demonstrate its effectiveness in reducing obesity-associated renal abnormality. Suggested mechanism was through reduction of cytokines, such as Toll-like Receptors (TLR) that are down-regulated by Vitamin D, hence reducing Interleukin-6 (IL-6) or by preventing abnormal growth of parathyroid hormone (PTH). The lipid droplets were found to be in a degenerative stage in mice fed High-Fat-Diet (HFD) with calcitriol treatment, which showed a causal relationship between calcitriol intake in renal tubules causing structural changes under HFD conditions [42]. A study that included people above 65 years of age suggested an increased risk of vitamin D deficiency in overweight and higher body fat percentages [43]. As previously mentioned, studies also support an inverse relationship between weight loss and Vitamin D serum changes. This is shown to be effective in eliminating obesity-related inflammation since significant reductions in levels of IL-6 were noted with intervention combining Vitamin D3 supplementation and weight-loss program [44]. Low serum 25(OH)D was found to be significantly associated with high serum IL-6 in overweight/obese children and with increased hs-CRP in obese children [45]. 1,25(OH)₂D₃ is also found to have a strong inhibitory effect on NFκB signalling in human adipocytes [46]. On the contrary, a meta-analysis conclusive of 13 RCT suggests that Vitamin-D supplementation does not affect inflammatory markers: CRP, TNF-α, IL-6 in overweight or obese subjects [47]. Some studies do not support any link between Vitamin D supplementation and obesity. Supplementation with vitamin D showed no effect on adiposity measures in adults [48]. An increase in serum levels of 25OHD or other inflammatory markers was not observed in overweight and obese youths with 150,000IU supplemented every 3 months, which demands investigation regarding potential dosage and frequency, [49] since another trial with dosage as low as 400IU up till 4800IU daily yielded serum changes when administered for 12 months [50].

Role of Vitamin D in other obesity mediated diseases

Chronic diseases are usually linked with obesity, which has been further explored in relation to Vitamin D status or to investigate the effectiveness of supplementation in attenuating related symptoms. Visceral obesity has been also found to be related with low levels of Vitamin D [51]. Visceral obesity is also highly correlated with Non-Alcoholic Fatty Liver disease (NAFLD) thus it is expected that Vitamin D is also related with NAFLD. A recent study in adults demonstrated the strong link between vitamin D and NAFLD [52]. The authors examined a total of 1081
adults and concluded that low vitamin D levels were highly associated with NAFLD independent of visceral obesity in subjects with Diabetes or insulin resistance [52]. BMI was also strongly associated with plasma 25- hydroxy Vitamin D, [25(OH)D] and PTH concentrations with possible influence of plasma 25(OH)D in the pathogenesis of hypertriglyceridermia and atherogenic dyslipidemia through inflammation, because the association disappeared when uCRP (ultrasensitive C-Reactive Protein) was introduced as covariable [53]. 25(OH)D low levels and unfavourable lipid patterns have been also found in children [54]. No effect on β-cell function or insulin action in obese non-diabetic adolescents was observed upon administration of Vitamin D3 supplementation [55]. A systematic review provides evidence of the insignificant effect of supplementation with vitamin D on glucose and insulin metabolism in overweight and obese individuals but a positive influence on the serum concentration of 25(OH)D [47]. Serum 25(OH)D level in diabetic patients (Type 2) was found to be inversely correlated with monocyte adhesion to endothelial cells. 1,25(OH)2D3 suppressed ER stress, [56] and promoted M1-predominant phenotype with lower endothelial adhesion. Vitamin D suppresses both subsets of monocytes, with M1 predominant, however, M1 is involved in advanced plaques compared to M2 in early stages in simple terms [57]. Real paradigms might be more complex and needs further research. A decrease in systolic blood pressure and adiposity in middle-aged subjects after a weight-loss intervention was observed with an increase in plasma 25(OH)D level [58]. Lower inflammatory profile, better insulin sensitivity, higher Vitamin D levels and IGF-1 (Insulin-like Growth Factor-1) in lean mass of obese patients recorded in the study suggest physical activity programs potential to create a better metabolic profile [59]. Hence, special programs to support a lifestyle that incorporate dietary changes and physical activity programs can be used to attain better Vitamin D levels with a range of other health benefits.

In addition, visfatin has been recently found to be associated with Vitamin D levels. Visfatin is a new adipokine involved in several processes. Visfatin plays an important role in inflammatory processes [60]. In a very recent study [61], the authors examined 50 patients with chronic hepatitis with elevated visfatin levels. After administration of vitamin D3 (15,000 IU/weekly), the patients’ visfatin levels were significantly reduced after a 12, 14, and 48-week period compared with the baseline data. The researchers concluded that Vitamin D supplementation may offer beneficial effects in reducing inflammation in these patients. More studies though are needed to elucidate these optimal effects.

In conclusion, the latest research on Vitamin D deficiency and obesity pandemic supports the role for Vitamin D in prevention and occurrence of obesity. Hence, public health sector needs to address the implying socio-economic aspects influencing Vitamin D status in order to prevent the burden of the disease which the possibly an outcome of Vitamin D deficiency. The adipokines secretion and inflammatory cytokines expression are importantly linked to Vitamin D metabolism. However, the mechanisms need further elucidation, as research is both equivocal and inadequate to establish a direct relationship in some cases. The role of visceral fat is stronger compared to subcutaneous fat in inflammation, related to obesity. The clinical trials identified in this paper usually involve Vitamin D supplementation in attaining sufficient Vitamin D levels, which indicates the need for trials to determine if same effects of Vitamin D can be observed with dietary sources too, as it is imperative in deciding on fortification of food across different socio-economic groups.

References


